Is there an investment opportunity in PSP Projects shares?

Is this the right time to invest in the shares of PSP Projects, a company that does construction work for the government and corporate India? How much benefit will there be from investing in this stock? What targets are experts giving regarding this stock? Watch this video to know-

  • Last Updated : April 26, 2024, 15:10 IST
Representative Image (Pixabay)

Natco Pharma rose 3.78% to Rs 911 after the company said that it is seeking an emergency approval of Molnupiravir capsules for Covid-19 treatment.

Natco Pharma has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.

Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy, the drug maker said in a statement.

Natco is hoping that CDSCO would give emergency approval of this drug based on compassionate use for patients. Compassionate use approval is given for investigational drugs so a patient with an immediately life-threatening condition can gain access to the drug. The company is ready to launch the product this month if approval is given.

The drug maker’s consolidated net profit dropped 39.3% to Rs 63.40 crore on 26.3% fall in net sales at Rs 355.20 crore in Q3 FY21 over Q3 FY20.

Natco Pharma manufactures a comprehensive range of branded and generic dosage forms, bulk actives and intermediates for both Indian as well as International markets.

Powered by Capital Market – Live News

Published: April 26, 2021, 10:48 IST
Exit mobile version